Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers

2009; American Association for Cancer Research; Volume: 15; Issue: 21 Linguagem: Inglês

10.1158/1078-0432.ccr-09-0536

ISSN

1557-3265

Autores

Rebecca Herbertson, Niall C. Tebbutt, Fook-Thean Lee, David Macfarlane, Bridget Chappell, Noel Micallef, Sze-Ting Lee, Timothy Saunder, Wendie Hopkins, Fiona E. Smyth, David Wyld, John Bellen, Daryl Sonnichsen, Martin W. Brechbiel, Carmel Murone, Andrew M. Scott,

Tópico(s)

Cancer Immunotherapy and Biomarkers

Resumo

This phase I study explored the biodistribution and pharmacokinetics of the immunoconjugate CMD-193 [a humanized anti-Lewis Y (Le(y)) antibody conjugated with calicheamicin in patients with advanced cancers expressing the Le(y) antigen.

Referência(s)